President Donald Trump said Monday he's in no rush to respond to a coordinated attack that hit Saudi Arabia's oil industry over the weekend.Marketsread more
The price of oil could go sharply higher, depending on the duration of the disruption at Saudi oil facilities and whether there is a military response.Powering the Futureread more
Energy stocks, one of the worst-performing sectors this year, spiked Monday after an attack on Saudi Arabia's heart of oil production Saturday sent oil prices soaring.Marketsread more
The Saudi-led military coalition battling Yemen's Houthi movement said on Monday that the attack on Saudi oil plants was carried out by Iranian weapons and did not originate...Oilread more
After a series of setbacks on the road to an initial public offering, the parent company of real estate start-up WeWork is delaying the move, sources told CNBC Monday.Technologyread more
"The United States military, with our interagency team, is working with our partners to address this unprecedented attack and defend the international rules-based order that...Politicsread more
Crude oil's spike following attacks on Saudi Arabia's energy supply has experts weighing whether or not the gains will last.ETF Edgeread more
"In the old days, the averages would've plunged on this kind of oil shock. I know because I've lived through a bunch of them, starting in 1973," Jim Cramer says.Mad Money with Jim Cramerread more
Traders in the fed funds futures market on Monday were pricing in a 34% chance that the Fed will stay put on rates.The Fedread more
The meeting comes amid months of stalled trade talks between Washington and New Delhi, resulting in both sides taking retaliatory measures.Asia Politicsread more
Gas prices could rise by about 20 cents per gallon "starting tomorrow," oil analyst Andy Lipow says Monday.Oil and Gasread more
(Adds background, company comments)
Sept 10 (Reuters) - The U.S. Food and Drug Administration has approved Xeris Pharmaceuticals Inc's glucagon pen that aims to treat severely low sugar levels in diabetes patients, the drugmaker said on Tuesday.
The condition, called hypoglycemia, can cause acute cognitive impairment. A mild or moderate fall in sugar levels, when left untreated, can result in cardiovascular disease, seizure, coma, and even death.
Gvoke, Xeris' glucagon pen is an pre-filled device with liquid stable form of glucagon. It won approval for use in diabetes patients, aged 2 years and above.
Long-term use of insulin can sometimes lead to side effects, including hypoglycemia. Severe hypoglycemia typically occurs in diabetics on insulin treatment.
There are 5.6 million type 1 and type 2 diabetics who are taking insulin and anyone on insulin should have glucagon handy, Chief Executive Officer Paul Edick said.
"Just about everyone who is a diabetic is going to have frequent low blood sugar, most of them once or twice a year are going to have a severe episode that needs rescue."
Eli Lilly and Co's Baqsimi was approved to treat hypoglycemia by the U.S. FDA in July, making it the first approved non-injectable glucagon therapy for the emergency treatment of the condition.
Glucagon is a hormone produced by the pancreas that is responsible for raising the concentration of glucose and fatty acids in the bloodstream.
Injectable form of glucagon, standard of care for treating hypoglycemia, has been approved for use in the United States for several decades. (Reporting by Aakash Jagadeesh Babu and Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber)